FEMARA 2,5 mg kohlpharma

Description

Directions for use

• Intravenously, regardless of food intake.
• If a dose is missed, it should be taken as soon as possible, but avoiding duplication (if the time for taking the next dose is almost due).
• Exceeding the daily dose >2.5 mg may increase systemic effects of the drug.
• Adults. The recommended dose of the drug is 2.5 mg once daily, daily, long-term.
• As prolonged adjuvant therapy the treatment should be continued for 5 years (not longer than 5 years).
• If signs of progression appear, the drug should be discontinued.
• In neoadjuvant (preoperative period) treatment with the drug should be continued for 4-8 months to achieve optimal reduction of tumour size. If adequate tumour response to treatment is not achieved, the drug should be discontinued, and surgical or other types of treatment should be considered.
• Patients with liver dysfunction
• In mild to moderate liver dysfunction, no dose adjustment is required (Child-Pugh class A or B). Data on the use in patients with severe liver dysfunction (Child-Pugh class C) are insufficient, therefore the use of the drug in such patients should be carried out under constant medical supervision.
• Patients with impaired renal function
• In renal dysfunction (creatinine clearance ≥10 ml/min) no dose adjustment is required. Data on use in patients with creatinine clearance <10 ml/min are insufficient.
• Patients aged ≥65 years old
• No dose adjustment is required in elderly patients.